Clinical update on COVID-19 for the emergency clinician: Presentation and evaluation

B Long, BM Carius, S Chavez, SY Liang… - The American journal of …, 2022 - Elsevier
Introduction Coronavirus disease of 2019 (COVID-19) has resulted in millions of cases
worldwide. As the pandemic has progressed, the understanding of this disease has evolved …

Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19

A Bonaventura, A Vecchié, L Dagna… - Nature Reviews …, 2021 - nature.com
Abstract Coronavirus disease 2019 (COVID-19) is a clinical syndrome caused by infection
with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients with severe …

Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study

I Katsoularis, O Fonseca-Rodríguez, P Farrington… - bmj, 2022 - bmj.com
Objective To quantify the risk of deep vein thrombosis, pulmonary embolism, and bleeding
after covid-19. Design Self-controlled case series and matched cohort study. Setting …

Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid …

M Sholzberg, GH Tang, H Rahhal, M AlHamzah… - bmj, 2021 - bmj.com
Objective To evaluate the effects of therapeutic heparin compared with prophylactic heparin
among moderately ill patients with covid-19 admitted to hospital wards. Design Randomised …

The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity

MF Osuchowski, MS Winkler, T Skirecki… - The Lancet …, 2021 - thelancet.com
The zoonotic SARS-CoV-2 virus that causes COVID-19 continues to spread worldwide, with
devastating consequences. While the medical community has gained insight into the …

Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes

DE Leisman, L Ronner, R Pinotti, MD Taylor… - The Lancet …, 2020 - thelancet.com
The description of a so-called cytokine storm in patients with COVID-19 has prompted
consideration of anti-cytokine therapies, particularly interleukin-6 antagonists. However …

Immunity, endothelial injury and complement-induced coagulopathy in COVID-19

L Perico, A Benigni, F Casiraghi, LFP Ng… - Nature Reviews …, 2021 - nature.com
In December 2019, a novel coronavirus was isolated from the respiratory epithelium of
patients with unexplained pneumonia in Wuhan, China. This pathogen, named severe acute …

The impact of COVID-19 disease on platelets and coagulation

GD Wool, JL Miller - Pathobiology, 2021 - karger.com
Abstract Coronavirus disease 2019 (COVID-19) causes a spectrum of disease; some
patients develop a severe proinflammatory state which can be associated with a unique …

COVID-19 in people with diabetes: understanding the reasons for worse outcomes

M Apicella, MC Campopiano, M Mantuano… - The lancet Diabetes & …, 2020 - thelancet.com
Since the initial COVID-19 outbreak in China, much attention has focused on people with
diabetes because of poor prognosis in those with the infection. Initial reports were mainly on …

Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial

G Lanzoni, E Linetsky, D Correa… - Stem cells …, 2021 - academic.oup.com
Acute respiratory distress syndrome (ARDS) in COVID-19 is associated with high mortality.
Mesenchymal stem cells are known to exert immunomodulatory and anti-inflammatory …